Giant Cell Arteritis (GCA)
Conditions
Brief summary
We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses. Early assessment of the rate of CRP normalization would enable us to adapt the therapeutic strategy in order to avoid complications and/or relapses.
Detailed description
Giant cell arteritis (GCA) is a chronic systemic vasculitis of the large vessels characterized by a significant inflammatory syndrome, correlated with disease activity and various inflammatory biomarkers, including CRP, which more effectively reflects disease activity. Relapses remain frequent, with rates of up to 45.7%. Recommended treatments involve long-term corticosteroid therapy and/or sparing therapies, which are associated with adverse events. Identifying relapsing patients is therefore crucial, in order to best adapt initial treatment and patient follow-up. We therefore propose to study CRP kinetics at diagnosis and at initiation of corticosteroid therapy, to determine the link with disease progression.
Interventions
DIAGNOSTIC_TESTBlood tests to measure CRP
Blood tests to measure CRP levels
Sponsors
University Hospital, Limoges
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients aged 18 or older hospitalized in the internal medicine department with a new diagnosis of ACG * Personne affiliée ou bénéficiaire d'un régime de sécurité sociale * Free and informed consent signed by the participant and the investigator
Exclusion criteria
* Patients scheduled to be placed on a sparing regimen during hospitalization * Patients with renal insufficiency (eGFR ≤ 60 mL/min/1.73 m²) * Patients with a history of corticosteroid-treated pseudopolyarthritis * Patients with ACG and visual impairment (severity criterion) * Patients on immunosuppressants or biologic therapy * HIV infection or progressive malignancy * Known poor treatment adherence * Dementia * Pregnant or breastfeeding women * Patients under legal guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CRP testing | 1 year | 1. Immediately before starting corticosteroids 2. Every day immediately before taking the morning dose of corticosteroids, for 5 days, and up to 7 days if levels do not return to normal 3. Then once a week for up to 1 month after starting corticosteroids 4. Then monthly for 8 months during follow-up visits 5. Then every 2 months for up to 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determining Corticosteroid Dosages and Estimating Their Half-Lives | 5 days | Corticosteroid Dosage: Take daily, just before your morning dose of corticosteroids |
Contacts
CONTACTKim LY, Professor
Outcome results
None listed